30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
Screening a 19,786-compound chemical diversity library, we identified > 100 compounds that corrected nuclear membrane defects in MAPT IVS10+16 neurons, with 23 demonstrating robust dose-dependent rescue. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD), the term “dementia”, describes a specific neuropathology together with the development and progression of age-related cognitive and functional loss. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) and related tauopathies such as frontotemporal dementia (FTD) or traumatic brain injury (TBI) are neurodegenerative disorders characterized by progressive loss of memory and cognitive function. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent discoveries indicating that the brain retains its ability to adapt and change throughout life have sparked interest in cognitive training (CT) as a possible means to postpone the development of dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
=3.40; P=.04). Greater cognitive improvements were associated with younger age, higher functional status, and lower baseline cognitive function. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to evaluate the effectiveness of the comprehensive dementia prevention application 'MELI' in enhancing cognitive function and alleviating depressive symptoms among older adults.A total of 50 participants aged 60 and older, enrolled in a dementia prevention program operated in Namdong-gu, Incheon, South Korea, were randomly assigned to either an experimental or a control group, with 25 participants in each. 1 key finding →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multidomain lifestyle interventions can improve cognitive function and mobile health technologies can deliver cost-effective interventions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The latter often experience a loss of functional independence and geriatric syndromes including falls, undernutrition and neurocognitive disorders (1) requiring significant care that generates health expenditure. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The first three elements concerned common awareness of collaborative ACP in dementia care, role clarification for various professions and actively working towards shared goals in collaborative ACP in dementia care. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of these, a growing number have secured funding, initiated collaborations, contributed to dementia palliative care research, and increased confidence and comfort with conducting clinical trials (p<.05). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence (AI) has gained attention as a tool to support dementia care through efficient and personalized interventions. 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 218 m6A sites significantly associated with the three diseases, highlighting 3,430 associations between m6A sites and gene expression. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Exposure to fine particulate matter (PM ) pollution is associated with negative health outcomes including dementia, cardiovascular disease (CVD), and stroke due to increased levels of oxidative stress and inflammation among community-dwelling older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Spatial transcriptomics (ST) represents a revolutionary approach in molecular biology, providing unprecedented insights into the spatial organization of gene expression within tissues. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Food choices profoundly impact population health and the environment. 2 key findings →
Participants: 290 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The median proportion of in-hospital LTC certification applications was 30.5% (IQR 24.5%-36.1%). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 1,035 patients in our dataset, 176 (17%) had a dementia diagnosis. 5 key findings →
Participants: 1,035 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Average county‐level ADRD prevalence was 11.06% across the pre‐expansion period and 7.15% post‐expansion. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The consequences of Alzheimer’s Disease and Related Dementias (ADRD) are well documented, but beyond the individual, family, and health system costs are implications for communities that are not well-studied. 5 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
. The area under the receiver operating characteristic curve of plasma p -tau217 was 0.941. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the study scenario, adding plasma p -tau217 testing to SCE reduced diagnostic costs by $342/patient, through more efficient use of amyloid PET and CSF testing. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In Part 1 (currently ongoing), between February 6, 2024, and December 27, 2024, 322 adults were screened, of whom 75 (aged 59-89 years) met NIA-AA and IPA criteria. 5 key findings →
Design: clinical trial Participants: 322 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The APOE (apolipoprotein E) ε4 allele is the strongest known genetic risk factor for sporadic Alzheimer disease (AD) and for brain amyloidosis, an early marker of disease pathophysiology. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our findings highlight the potential of diverse genomic backgrounds to uncover protective genetic factors, such as the African-specific protective PSG2 locus, found to confer a protective effect among APOE4 carriers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events